

declaration also presents *in vivo* data obtained in an established murine asthma model (ovalbumin or "OVA"-sensitized mice) that clearly confirms the use of such CCR4 antagonists in treating asthma. This model is accepted in the art as a reasonable predictor of human allergic inflammation, particularly asthma. Please see the references included in the accompanying information disclosure statement that document the wide-spread use of the OVA murine model to predict efficacy in man.

For at least the foregoing reasons, Applicants believe the claims are enabled and request withdrawal of the enablement rejection of claims 1, 2, 5, 6 and 13 for lack of utility.

Fees


No additional fees should be due, however, if it is determined that an additional fee is due, please charge same to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Summary

Applicants believe the claims are in condition for allowance. The Examiner is invited to contact the undersigned by telephone, at the number listed below, if it is believed that a telephonic communication would facilitate the prosecution of this application.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
609-252-5323


Laurelee A. Duncan.
Attorney for Applicants
Reg. No. 44,096

Date: October 17, 2006